Pharmacokinetic Variability of Daptomycin During Prolonged Therapy for Bone and Joint Infections
|ClinicalTrials.gov Identifier: NCT03209921|
Recruitment Status : Completed
First Posted : July 6, 2017
Last Update Posted : July 6, 2017
Daptomycin is a cyclic lipopeptide that has been proposed as an alternative therapeutic option in patients with prosthetic joint infection caused by Staphylococcus or Enterococcus species in the latest Infectious Diseases Society of America (IDSA) guidelines.
The population pharmacokinetics (PK) of daptomycin have been described in various groups of patients in previous publications. However, little information exists on the PK of daptomycin in patients with bone and joint infections (BJI). Also, previous population studies did not investigate daptomycin PK over prolonged therapy, and, to our knowledge, no study has reported the intraindividual PK variability of this drug.
The aim of this study is to describe the inter- and intraindividual PK variability of this drug.
|Condition or disease|
|Bone and Joint Infection Patient Treated by Daptomycin|
|Study Type :||Observational|
|Actual Enrollment :||23 participants|
|Official Title:||Pharmacokinetic Variability of Daptomycin During Prolonged Therapy for Bone and Joint Infections|
|Actual Study Start Date :||May 2015|
|Actual Primary Completion Date :||September 2015|
|Actual Study Completion Date :||September 2015|
- Typical daptomycin clearance [ Time Frame: 6 months ]
Mean daptomycin plasma clearance (unit, liters per hour)
Outcome measures performed regularly in those patients throughout therapy, roughly every month.
- Typical daptomycin volume of distribution [ Time Frame: 6 months ]Mean daptomycin volume of distribution (unit, liters) in the population